interferon

• Ainos's low-dose oral interferon therapy VELDONA has shown significant anti-inflammatory effects in cats with Feline Chronic Gingivostomatitis, with inflammation score improvements ranging from 10.5% to 44.4% in initial trial participants. • The treatment demonstrated a notable steroid-sparing effect, allowing complete discontinuation of steroid therapy in two cases and dose reduction in another, potentially addressing a critical unmet need in veterinary medicine. • With no significant side effects observed, VELDONA positions Ainos to potentially capture a share of the global pet dental market, projected to reach $13 billion by 2030.

A large VA healthcare system study reveals that direct-acting antiviral (DAA) therapy significantly reduces hepatocellular carcinoma risk compared to no treatment in HCV patients with cirrhosis.

A large-scale retrospective study utilizing TriNetX database demonstrates that psoriasis patients face a 50% higher risk of developing Sjögren's syndrome compared to non-psoriasis individuals.

Arbutus Biopharma plans to initiate a Phase 2b clinical trial of imdusiran, combined with interferon and nucleos(t)ide analogue therapy, in the first half of 2025 for cHBV.

Cenerimod 4 mg significantly reduced interferon (IFN)-associated protein and gene signature biomarkers in SLE patients after 6 months compared to placebo.